Core Viewpoint - The article discusses the implementation of the commercial insurance drug directory (商保目录) in China, highlighting its significance for innovative drugs and the challenges faced in its execution [2][3][15]. Group 1: Overview of the Commercial Insurance Drug Directory - The commercial insurance drug directory includes 19 drugs, including CAR-T therapies and Alzheimer's medications, aimed at addressing the gap between basic medical insurance and patient affordability [2][3]. - As of January 20, 2026, 14 drugs from the directory have been sold in 223 designated medical institutions, primarily in major cities [5][6]. - The directory's implementation is seen as a milestone for the development of innovative drugs and commercial insurance in China, although many people have yet to feel its impact [2][3]. Group 2: Challenges in Implementation - The main challenge for hospitals is the process of getting drugs from the directory into their facilities, which involves multiple evaluations and approvals [5][6]. - Hospitals are cautious about introducing new drugs due to cost control pressures and various performance indicators that must be met [7][12]. - The "three exclusions" policy aims to alleviate concerns about the financial impact of new drugs on hospitals, but other factors still influence the decision to adopt these drugs [7][12]. Group 3: Discount and Pricing Issues - The commercial insurance directory allows for negotiated discounts on drug prices, which are not directly passed on to patients at the point of sale [9][10]. - There is confusion among stakeholders regarding how these discounts should be allocated, leading to potential disputes in implementation [10][11]. - The lack of clear guidelines on discount distribution complicates the relationship between insurance companies, drug manufacturers, and healthcare providers [10][11]. Group 4: Insurance Companies' Perspectives - Insurance companies are cautious about incorporating drugs from the directory into their products, often requiring detailed information on pricing and risk before making decisions [13][14]. - There is a lack of new insurance products specifically designed for the commercial insurance directory, with most companies opting to upgrade existing products [13][14]. - The directory's introduction is viewed positively by some pharmaceutical companies, as it represents government endorsement of their products, although challenges remain in achieving widespread adoption [15][16].

Core Viewpoint - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have issued new guidelines for the integration of commercial health insurance with the national basic medical insurance system, focusing on innovative drugs and their accessibility for patients [1][2] Group 1: Policy Implementation - Provincial healthcare security departments are required to implement the measures outlined in the notification regarding the support for high-quality development of innovative drugs [1] - The commercial health insurance directory for innovative drugs will not be covered by the medical insurance fund and will not be included in the self-pay rate indicators for designated medical institutions [1] Group 2: Support for Innovative Drugs - The application cases of innovative drugs listed in the commercial health insurance directory will not be included in the payment scope under the disease-based payment system, but can be reimbursed after review [1] - Provincial departments may explore the support for retail pharmacies to stock innovative drugs from the commercial health insurance directory and monitor pricing at medical institutions and retail pharmacies [1] Group 3: Multi-layered Medical Security System - Local healthcare departments are encouraged to promote the construction of a multi-layered medical security system and support the development of inclusive commercial health insurance [2] - Commercial insurance institutions are encouraged to design new products and adjust compensation methods based on the commercial health insurance directory to better meet patient medication needs [2]